Pendleton Todd sold $648K of DLB

Pendleton Todd (SVP, Chief Marketing Officer) sold 11,876 shares of Dolby Laboratories, Inc. (DLB) at $54.55 ($0.65M total) on 2026-05-22.

Original reporting
SEC EDGAR · Pendleton Todd
Published May 27, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DLB
Neutral
high confidence
Mentioned
$DLB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DLBNeutralLow
01

Why it matters

Insider sale disclosures can modestly influence short-term sentiment, but without accompanying company catalysts they rarely drive sustained repricing.

02

Market read

Traders may monitor for sentiment/positioning signals, but the disclosure alone is unlikely to change valuation assumptions.

03

What to watch

No 10b5-1 plan is cited; however, absence of a plan in the snippet doesn’t establish intent, and the article provides no follow-on context (e.g., earnings proximity, performance-based vesting).

Relevance 6/10Timing: Same-day/next-session attention possible, but typically fades quickly for routine Form 4 sales.

Background

The article is an SEC Form 4 insider transaction filing (open-market sale) for Dolby Laboratories shares by a named executive.

Company-level read

Ticker impact

$DLBNeutralHigh confidence
Context

Dolby Laboratories insider Pendleton Todd (SVP, Chief Marketing Officer) sold 11,876 shares in an open-market transaction disclosed on Form 4.

Expected impact

Likely limited near-term impact; any move would be more sentiment/flow-driven than fundamentals.

Evidence & confidence

The filing is an open-market sale with no 10b5-1 plan stated and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; insider transactions generally do not reset sector expectations without linked operational or guidance changes.

None indicated; disclosure is company-specific and not tied to broader regional demand/supply shocks.

None indicated; no international contract, trial, or regulatory development mentioned.

Counterpoint

The sale could reflect diversification or tax/liquidity needs and may not imply negative views on Dolby’s prospects.

Key entities

  • Dolby Laboratories, Inc.

    Subject of the Form 4 insider sale by SVP/Chief Marketing Officer Pendleton Todd.

  • Pendleton Todd

    SVP, Chief Marketing Officer who sold 11,876 shares at ~$54.5518 on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$DLBMed

Dolby Laboratories Q4 Earnings Call Highlights

Dolby Laboratories reported Q4 earnings with Atmos, Vision, and imaging patents revenue growing 18%, surpassing foundational audio. The company expects mid-single-digit declines in foundational audio and similar growth in other segments for fiscal 2027. New CEO Kevin Whitten focuses on AI and recurring revenue. Dolby anticipates Q1 revenue of $285M-$305M and full-year non-GAAP operating expenses of $775M. The company has $713M in cash and no debt, repurchasing $265M in shares in fiscal 2026.

$DLBMedAI 9/10

Dolby Laboratories Profit Advances In Q4

Dolby Laboratories (DLB) reported Q4 earnings of $80.9M ($0.86 per share), up from $49.3M ($0.51 per share) last year. Adjusted earnings were $117.8M ($1.25 per share). Revenue increased 21.7% to $373.5M. The company guided next quarter's EPS to $0.41-$0.56 and revenue to $285M-$305M.